Tissue diagnostic methods are mostly utilized to comprehend the preserved antigens in particular tissues. It entails diagnosis, monitoring, and management of diverse cancer stages, particular gastric cancer, prostate cancer, and breast cancer, among others.
The key factors driving the growth of global tissue diagnostics market include the rising cancer prevalence, growing expenditure for healthcare, enhancing cancer diagnostics infrastructure, and numerous technological developments in the field of tissue diagnostics. Further, with the growing life expectancy and decreasing rates of fertility, the overall segment of the elderly people is witnessing steady growth at present globally. This is a vital factor adding to the expansion of the market as elderly people are more prone to chronic diseases and thereby need regular diagnoses and check-ups. Also, research institutes are implementing automated tissue-based diagnostic systems at an increase rate allowing them to carry out rapid tumor diagnosis. To cite, West Clinic Cancer Center, in September 2019, collaborated with F. Hoffmann-La Roche Ltd. to enhance patient care by making use of BenchMark ULTRA Automated Advanced Staining System of Roche.
Get Sample of this Research Report for more Insights – https://www.zionmarketresearch.com/sample/tissue-diagnostics-market
The global tissue diagnostics market can be segmented based on technology, product, end user, disease, and region. The market, by product, is diversified into instruments and consumables. The instruments segment is further sub-segmented into scanners tissue-processing systems, slide-staining systems, and others. The consumables segment is further sub-segmented into kits, antibodies, probes, and reagents. The market, by disease, is categorized into gastric cancer, non-small cell lung cancer, breast cancer, prostate cancer, lymphoma, and other diseases. The market, by technology, is divided into in situ hybridization, immunohistochemistry, special staining, and digital pathology & workflow management. The market, by end user, is categorized into pharmaceutical companies, hospitals, ambulatory surgical centers, diagnostic centers, research laboratories, and others.
North America is anticipated to rule the global tissue diagnostics market during the forecast period on account of elevating consciousness among people regarding the potential advantages of diagnostics along with swiftly rising aging population. Also, the growing disease burden is again driving the requirement for quick and effective treatment options which, in turn, will fuel the market growth in the near future. Likewise, Asia Pacific is projected to witness a considerable growth during the forecast period on account of growing access to a number of tissue diagnostic assays offered by international firms together with escalating population base and increasing incidence of chronic diseases.
The major players actively participating in the global tissue diagnostics market include Danaher Corporation, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies, Inc., Abcam plc., Sakura Finetek Japan Co., Ltd., QIAGEN, Becton, Dickinson, and Company, BioGenex, Bio SB, 3DHISTECH Ltd., Cell Signaling Technology, Inc., and Cancer Genetics Inc., among others.
